Phase 3 Clinical Trials With Primary Completion Dates in August 2023

This is a list of Phase 3 trials with primary completion dates in August 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ACAD ACADIA Pharmaceuticals Inc. 2023-08-01 Phase 3 NCT03623321 Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
ALVO Alvotech 2023-08-01 Phase 3 NCT05155293 Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
BVNRY Bavarian Nordic A/S 2023-08-01 Phase 3 NCT02977715 IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo
CBAY CymaBay Therapeutics, Inc. 2023-08-01 Phase 3 NCT04620733 RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
DNLI Denali Therapeutics Inc. 2023-08-01 Phase 3 NCT05418673 A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
ITCI Intra-Cellular Therapies, Inc. 2023-08-01 Phase 3 NCT04985942 Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
LIAN LianBio 2023-08-01 Phase 3 NCT05629390 Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study
MNKD MannKind Corporation 2023-08-01 Phase 3 NCT04974528 Afrezza® INHALE-1 Study in Pediatrics
NAVB Navidea Biopharmaceuticals, Inc. 2023-08-01 Phase 3 NCT05246280 Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
NBIX Neurocrine Biosciences, Inc. 2023-08-01 Phase 3 NCT04490915 Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
SLNO Soleno Therapeutics, Inc. 2023-08-01 Phase 3 NCT03714373 Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
TVTX Travere Therapeutics, Inc. 2023-08-01 Phase 3 NCT03762850 A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy